Einzeltreffer — DigiBib

The global pandemic of COVID-19 caused by SARS-CoV-2 (also known as 2019-nCoV and HCoV-19) has posed serious threats to public health and economic stability worldwide, thus calling for development of vaccines against SARS-CoV-2 and other emerging and reemerging coronaviruses. Since SARS-CoV-2 and SARS-CoV have high similarity of their genomic sequences and share the same cellular receptor (ACE2), it is essential to learn the lessons and experiences from the development of SARS-CoV vaccines for the development of SARS-CoV-2 vaccines. In this review, we summarized the current knowledge on the advantages and disadvantages of the SARS-CoV vaccine candidates and prospected the strategies for the development of safe, effective and broad-spectrum coronavirus vaccines for prevention of infection by currently circulating SARS-CoV-2 and other emerging and reemerging coronaviruses that may cause future epidemics or pandemics.

Competing Interests: Declaration of Competing Interest The authors declare no conflict of interest.

Titel:	From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development.
Autor/in / Beteiligte Person:	Ma, C ; Su, S ; Wang, J ; Wei, L ; Du, L ; Jiang, S
Link:	Full Text Finder (Volltext)
Zeitschrift:	Microbes and infection, Jg. 22 (2020-07-01), Heft 6-7, S. 245-253
Veröffentlichung:	Paris ; New York : Elsevier, c1999-, 2020
Medientyp:	academicJournal
ISSN:	1769-714X (electronic)
DOI:	10.1016/j.micinf.2020.05.004
Schlagwort:	Animals Betacoronavirus genetics COVID-19 COVID-19 Vaccines Coronavirus Infections classification Coronavirus Infections immunology Cross Protection Humans Pneumonia, Viral immunology SARS-CoV-2 Severe Acute Respiratory Syndrome immunology Vaccines, Inactivated immunology Viral Vaccines classification Coronavirus Infections prevention & control Pandemics prevention & control Pneumonia, Viral prevention & control Severe Acute Respiratory Syndrome prevention & control Viral Vaccines immunology
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review Language: English [Microbes Infect] 2020 Jul - Aug; Vol. 22 (6-7), pp. 245-253. <i>Date of Electronic Publication: </i>2020 May 11. MeSH Terms: Coronavirus Infections / prevention & control ; Pandemics / prevention & control ; Pneumonia, Viral / prevention & control ; Severe Acute Respiratory Syndrome / prevention & control ; Viral Vaccines / *immunology ; Animals ; Betacoronavirus / genetics ; COVID-19 ; COVID-19 Vaccines ; Coronavirus Infections / classification ; Coronavirus Infections / immunology ; Cross Protection ; Humans ; Pneumonia, Viral / immunology ; SARS-CoV-2 ; Severe Acute Respiratory Syndrome / immunology ; Vaccines, Inactivated / immunology ; Viral Vaccines / classification References: Hong Kong Med J. 2012 Feb;18 Suppl 2:31-6. (PMID: 22311359) ; Biochem Biophys Res Commun. 2004 Nov 12;324(2):773-81. (PMID: 15474494) ; J Gen Virol. 2000 Dec;81(Pt 12):2867-2871. (PMID: 11086117) ; Lancet. 2003 May 24;361(9371):1761-6. (PMID: 12781533) ; J Virol. 2004 Jun;78(11):5642-50. (PMID: 15140961) ; Emerg Microbes Infect. 2020 Dec;9(1):382-385. (PMID: 32065055) ; Virus Res. 2005 Sep;112(1-2):24-31. (PMID: 16022898) ; Lancet. 2020 Feb 15;395(10223):514-523. (PMID: 31986261) ; Nature. 2020 Mar;579(7798):270-273. (PMID: 32015507) ; Structure. 2006 May;14(5):889-99. (PMID: 16698550) ; Vaccine. 2008 Mar 20;26(13):1644-51. (PMID: 18289745) ; Cell Mol Immunol. 2020 May;17(5):554. (PMID: 32024976) ; Emerg Infect Dis. 2005 Jul;11(7):1016-20. (PMID: 16022774) ; Viral Immunol. 2010 Apr;23(2):211-9. (PMID: 20374001) ; Lancet. 2020 Feb 22;395(10224):565-574. (PMID: 32007145) ; Int Immunol. 2004 Oct;16(10):1423-30. (PMID: 15314040) ; J Med Virol. 2020 Apr;92(4):455-459. (PMID: 31994738) ; Nat Biotechnol. 2010 Jun;28(6):573-9. (PMID: 20531338) ; N Engl J Med. 2020 Mar 26;382(13):1199-1207. (PMID: 31995857) ; Lancet. 2004 Jun 26;363(9427):2122-7. (PMID: 15220033) ; Nature. 2003 May 29;423(6939):467. (PMID: 12774078) ; Cell Res. 2020 Apr;30(4):343-355. (PMID: 32231345) ; Comput Biol Chem. 2005 Jun;29(3):254-7. (PMID: 15979045) ; Emerg Microbes Infect. 2020 Dec;9(1):275-277. (PMID: 32005086) ; Vaccine. 2006 Jun 29;24(26):5498-508. (PMID: 16725238) ; J Virol. 2005 Mar;79(5):2678-88. (PMID: 15708987) ; Biochem Biophys Res Commun. 2004 Mar 19;315(4):1134-9. (PMID: 14985131) ; Vaccine. 2007 Jan 8;25(4):729-40. (PMID: 17049691) ; Drugs Today (Barc). 2008 Jan;44(1):63-73. (PMID: 18301805) ; Science. 2003 Oct 10;302(5643):276-8. (PMID: 12958366) ; J Virol. 2012 Apr;86(7):3995-4008. (PMID: 22278237) ; N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945) ; Virology. 2005 Mar 30;334(1):74-82. (PMID: 15749124) ; Antiviral Res. 2016 Sep;133:165-77. (PMID: 27468951) ; J Virol. 2008 Jul;82(14):6984-91. (PMID: 18448527) ; Antivir Ther. 2007;12(7):1107-13. (PMID: 18018769) ; Physiol Genomics. 2004 Jul 08;18(2):245-8. (PMID: 15161967) ; Nat Rev Microbiol. 2007 Jul;5(7):518-28. (PMID: 17558424) ; Virol Sin. 2018 Apr;33(2):201-204. (PMID: 29541941) ; N Engl J Med. 2020 Feb 27;382(9):872-874. (PMID: 31991079) ; FEBS Lett. 2006 Oct 16;580(24):5612-20. (PMID: 16989815) ; Annu Rev Virol. 2016 Sep 29;3(1):237-261. (PMID: 27578435) ; Nat Rev Microbiol. 2009 Mar;7(3):226-36. (PMID: 19198616) ; J Biol Chem. 2004 Jan 30;279(5):3197-201. (PMID: 14670965) ; JCI Insight. 2019 Feb 21;4(4):. (PMID: 30830861) ; Nat Commun. 2015 Jul 28;6:7712. (PMID: 26218507) ; Sci Rep. 2016 Nov 28;6:37131. (PMID: 27892522) ; Nature. 2013 Jun 20;498(7454):380-4. (PMID: 23722158) ; J Virol. 2007 Nov;81(21):12029-39. (PMID: 17715238) ; Biochem Biophys Res Commun. 2014 Aug 22;451(2):208-14. (PMID: 25073113) ; J Biol Chem. 2012 Mar 16;287(12):8904-11. (PMID: 22291007) ; Immunol Lett. 2004 Sep;95(2):139-43. (PMID: 15388253) ; Virology. 2006 Sep 15;353(1):6-16. (PMID: 16793110) ; Antiviral Res. 2013 Oct;100(1):246-54. (PMID: 23994189) ; Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15748-53. (PMID: 15496474) ; Cell Mol Immunol. 2016 Mar;13(2):180-90. (PMID: 25640653) ; DNA Cell Biol. 2005 Aug;24(8):510-5. (PMID: 16101349) ; Innovation (Camb). 2020 Nov 25;1(3):100048. (PMID: 33521762) ; Science. 2020 Feb 21;367(6480):. (PMID: 32079747) ; EMBO J. 2005 Apr 20;24(8):1634-43. (PMID: 15791205) ; Emerg Microbes Infect. 2017 May 24;6(5):e37. (PMID: 28536429) ; J Virol. 2006 Jun;80(12):5757-67. (PMID: 16731915) ; PLoS One. 2012;7(11):e50366. (PMID: 23185609) ; Nat Rev Drug Discov. 2020 May;19(5):305-306. (PMID: 32273591) ; N Engl J Med. 2020 Mar 5;382(10):929-936. (PMID: 32004427) ; J Virol. 2020 Mar 17;94(7):. (PMID: 31996437) ; Lancet. 2020 Feb 29;395(10225):689-697. (PMID: 32014114) ; Microbes Infect. 2020 Mar;22(2):74-79. (PMID: 32017984) ; Nat Med. 2008 Feb;14(2):154-61. (PMID: 18246077) ; J Virol. 2004 Nov;78(22):12672-6. (PMID: 15507655) ; Expert Opin Ther Targets. 2017 Feb;21(2):131-143. (PMID: 27936982) ; Epidemiology. 2005 Nov;16(6):791-801. (PMID: 16222170) ; Vaccine. 2007 Apr 12;25(15):2832-8. (PMID: 17092615) ; Sci Adv. 2019 Apr 10;5(4):eaav4580. (PMID: 30989115) ; Trends Microbiol. 2016 Jun;24(6):490-502. (PMID: 27012512) ; Expert Rev Vaccines. 2014 Jun;13(6):761-74. (PMID: 24766432) ; Nature. 2020 Mar;579(7799):321. (PMID: 32179860) ; Lancet. 2003 Oct 25;362(9393):1353-8. (PMID: 14585636) ; Viruses. 2019 Jan 14;11(1):. (PMID: 30646569) ; J Immunol. 2006 May 15;176(10):6085-92. (PMID: 16670317) ; Virology. 2009 Oct 10;393(1):144-50. (PMID: 19683779) ; J Virol. 2011 Oct;85(20):10582-97. (PMID: 21775467) ; Annu Rev Med. 2010;61:105-19. (PMID: 19824815) ; Biochem Biophys Res Commun. 2009 Jul 10;384(4):486-90. (PMID: 19422787) ; Virol Sin. 2020 Jun;35(3):263-265. (PMID: 32060789) ; Nat Microbiol. 2020 Apr;5(4):536-544. (PMID: 32123347) ; Vaccine. 2014 Oct 21;32(46):6170-6176. (PMID: 25240756) ; Trends Microbiol. 2015 Aug;23(8):468-78. (PMID: 26206723) ; Science. 2013 Feb 15;339(6121):826-30. (PMID: 23258412) ; Nat Rev Microbiol. 2019 Mar;17(3):181-192. (PMID: 30531947) ; Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264) ; Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5. (PMID: 16169905) ; PLoS One. 2012;7(4):e35421. (PMID: 22536382) ; ACS Infect Dis. 2016 May 13;2(5):361-76. (PMID: 27627203) ; Nat Med. 2012 Dec;18(12):1820-6. (PMID: 23142821) ; Adv Exp Med Biol. 2001;494:341-7. (PMID: 11774490) ; Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6. (PMID: 15096611) ; Biochem Biophys Res Commun. 2006 May 26;344(1):106-13. (PMID: 16615996) ; Chem Biol Drug Des. 2009 Jan;73(1):53-61. (PMID: 19152635) ; J Immunol. 2008 Jan 15;180(2):948-56. (PMID: 18178835) ; Philos Trans R Soc Lond B Biol Sci. 2021 Jul 19;376(1829):20200265. (PMID: 34053269) ; Adv Exp Med Biol. 2009;611:153-4. (PMID: 19400136) ; Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143) ; Science. 2013 Sep 20;341(6152):1390-4. (PMID: 23989956) ; J Immunol. 2005 Apr 15;174(8):4908-15. (PMID: 15814718) ; J Biol Chem. 2005 Aug 19;280(33):29588-95. (PMID: 15980414) ; DNA Cell Biol. 2004 Jun;23(6):391-4. (PMID: 15231072) ; Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2430-5. (PMID: 15695582) ; Virology. 2005 Apr 25;335(1):34-45. (PMID: 15823604) ; Cell. 2020 May 14;181(4):905-913.e7. (PMID: 32333836) ; Biochem Biophys Res Commun. 2004 Dec 10;325(2):445-52. (PMID: 15530413) ; J Med Virol. 2020 Apr;92(4):408-417. (PMID: 31944312) ; Commun Biol. 2018 Oct 29;1:179. (PMID: 30393776) ; Science. 2005 Oct 28;310(5748):676-9. (PMID: 16195424) ; Trends Microbiol. 2017 Jan;25(1):35-48. (PMID: 27743750) ; Vaccine. 2008 Nov 25;26(50):6338-43. (PMID: 18824060) ; Cell Mol Immunol. 2020 Jul;17(7):765-767. (PMID: 32047258) ; Cell. 2020 May 14;181(4):894-904.e9. (PMID: 32275855) Contributed Indexing: Keywords: 2019-nCoV; Cross-protection; HCoV-19; SARS-CoV; SARS-CoV-2; Vaccine Substance Nomenclature: 0 (COVID-19 Vaccines) ; 0 (Vaccines, Inactivated) ; 0 (Viral Vaccines) Entry Date(s): Date Created: 20200522 Date Completed: 20200814 Latest Revision: 20240328 Update Code: 20240329 PubMed Central ID: PMC7211703

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development.